share_log

Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) Largest Shareholders Are Individual Investors Who Were Rewarded as Market Cap Surged US$58m Last Week

Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) Largest Shareholders Are Individual Investors Who Were Rewarded as Market Cap Surged US$58m Last Week

Corbus 制药控股有限公司”s(纳斯达克股票代码:CRBP)的最大股东是个人投资者,上周市值飙升5800万美元,他们获得了回报
Simply Wall St ·  05/10 06:15

Key Insights

关键见解

  • Significant control over Corbus Pharmaceuticals Holdings by individual investors implies that the general public has more power to influence management and governance-related decisions
  • The top 8 shareholders own 51% of the company
  • Institutional ownership in Corbus Pharmaceuticals Holdings is 26%
  • 个人投资者对Corbus Pharmicals Holdings的严格控制意味着公众拥有更大的影响管理和治理相关决策的权力
  • 前8名股东拥有公司51%的股份
  • 科布斯制药控股公司的机构所有权为26%

If you want to know who really controls Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), then you'll have to look at the makeup of its share registry. We can see that individual investors own the lion's share in the company with 39% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

如果你想知道谁真正控制着Corbus Pharmicals Holdings, Inc.(纳斯达克股票代码:CRBP),那么你必须看看其股票登记处的构成。我们可以看到,个人投资者拥有公司的大部分股份,所有权为39%。换句话说,该集团将从对公司的投资中获得最多(或损失最大)。

Clearly, individual investors benefitted the most after the company's market cap rose by US$58m last week.

显然,在上周该公司的市值上涨了5800万美元之后,个人投资者受益最大。

In the chart below, we zoom in on the different ownership groups of Corbus Pharmaceuticals Holdings.

在下图中,我们放大了Corbus Pharmicals Holdings的不同所有权群体。

ownership-breakdown
NasdaqCM:CRBP Ownership Breakdown May 10th 2024
纳斯达克公司:CRBP 所有权明细 2024 年 5 月 10 日

What Does The Institutional Ownership Tell Us About Corbus Pharmaceuticals Holdings?

关于Corbus Pharmicals Holdings,机构所有权告诉我们什么?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

许多机构根据近似于当地市场的指数来衡量自己的表现。因此,他们通常会更多地关注主要指数中包含的公司。

We can see that Corbus Pharmaceuticals Holdings does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Corbus Pharmaceuticals Holdings' historic earnings and revenue below, but keep in mind there's always more to the story.

我们可以看到,Corbus Pharmicals Holdings确实有机构投资者;他们持有该公司很大一部分股票。这表明专业投资者有一定的信誉。但是我们不能仅仅依靠这个事实,因为机构有时会像所有人一样进行不良投资。当多家机构拥有一只股票时,总是存在处于 “拥挤交易” 的风险。当这样的交易出错时,多方可能会竞相快速出售股票。对于没有增长历史的公司,这种风险更高。你可以在下面看到Corbus Pharmicals Holdings的历史收益和收入,但请记住,故事总是有更多内容。

earnings-and-revenue-growth
NasdaqCM:CRBP Earnings and Revenue Growth May 10th 2024
纳斯达克股票代码:CRBP 收益和收入增长 2024 年 5 月 10 日

It looks like hedge funds own 32% of Corbus Pharmaceuticals Holdings shares. That worth noting, since hedge funds are often quite active investors, who may try to influence management. Many want to see value creation (and a higher share price) in the short term or medium term. The company's largest shareholder is Cormorant Asset Management, LP, with ownership of 19%. With 7.6% and 5.2% of the shares outstanding respectively, Adage Capital Management, L.P. and Millennium Management LLC are the second and third largest shareholders.

看来对冲基金拥有Corbus Pharmicals Holdings32%的股份。这值得注意,因为对冲基金通常是非常活跃的投资者,他们可能会试图影响管理层。许多人希望在短期或中期内看到价值创造(以及更高的股价)。该公司的最大股东是Cormorant资产管理有限责任公司,其所有权为19%。Adage Capital Management、L.P. 和千禧管理有限责任公司分别拥有7.6%和5.2%的已发行股份,是第二和第三大股东。

We did some more digging and found that 8 of the top shareholders account for roughly 51% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat.

我们做了进一步的挖掘,发现大股东中有8人约占登记册的51%,这意味着除了较大的股东外,还有一些较小的股东,从而在一定程度上平衡了彼此的利益。

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage.

虽然研究公司的机构所有权数据是有意义的,但研究分析师的情绪以了解风向哪个方向吹来也是有意义的。分析师对该股的报道很少,但报道不多。因此,它还有获得更多报道的余地。

Insider Ownership Of Corbus Pharmaceuticals Holdings

Corbus 制药控股公司的内部所有权

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

公司内部人员的定义可能是主观的,并且在不同的司法管辖区之间确实有所不同。我们的数据反映了个人内部人士,至少涵盖了董事会成员。公司管理层对董事会负责,后者应代表股东的利益。值得注意的是,有时高层管理人员自己也是董事会成员。

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

我通常认为内部所有权是一件好事。但是,在某些情况下,这使其他股东更难追究董事会对决策的责任。

Our data suggests that insiders own under 1% of Corbus Pharmaceuticals Holdings, Inc. in their own names. We do note, however, it is possible insiders have an indirect interest through a private company or other corporate structure. It has a market capitalization of just US$445m, and the board has only US$927k worth of shares in their own names. Many investors in smaller companies prefer to see the board more heavily invested. You can click here to see if those insiders have been buying or selling.

我们的数据显示,内部人士以自己的名义拥有Corbus Pharmicals Holdings, Inc.不到1%的股份。但是,我们确实注意到,内部人士有可能通过私营公司或其他公司结构获得间接利益。它的市值仅为4.45亿美元,董事会以自己的名义持有价值92.7万美元的股票。许多小型公司的投资者更愿意看到董事会加大投资力度。你可以点击这里查看这些内部人士是否在买入或卖出。

General Public Ownership

一般公有制

The general public-- including retail investors -- own 39% stake in the company, and hence can't easily be ignored. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

包括散户投资者在内的公众拥有该公司39%的股份,因此不容忽视。这种所有权规模虽然可观,但如果决定与其他大股东不同步,可能不足以改变公司的政策。

Private Company Ownership

私人公司所有权

Our data indicates that Private Companies hold 3.3%, of the company's shares. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.

我们的数据显示,私营公司持有公司3.3%的股份。仅凭这一事实很难得出任何结论,因此值得研究谁拥有这些私营公司。有时,内部人士或其他关联方通过一家独立的私人公司对上市公司的股份拥有权益。

Next Steps:

后续步骤:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. For instance, we've identified 5 warning signs for Corbus Pharmaceuticals Holdings (3 don't sit too well with us) that you should be aware of.

我觉得看看究竟谁拥有一家公司非常有趣。但是,要真正获得见解,我们还需要考虑其他信息。例如,我们已经确定了Corbus Pharmicals Holdings的5个警告信号(其中3个对我们不太满意),你应该注意这些信号。

Ultimately the future is most important. You can access this free report on analyst forecasts for the company.

归根结底,未来是最重要的。您可以访问这份关于公司分析师预测的免费报告。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注意:本文中的数字是使用过去十二个月的数据计算得出的,这些数据是指截至财务报表日期当月最后一天的12个月期间。这可能与全年年度报告数据不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发